Chronic gingivostomatitis treatment market
Chronic Gingivostomatitis Treatment Market, by Diagnosis (Physical Examination, Microbial Culture, Biopsy, and Others), by Treatment (Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, and Others), by End User (Hospitals & Clinics, Academic & Research, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
- Dec 2020
- CMI4308
- 180 Pages
- Excel & Pdf
- Pharmaceutical
Chronic gingivostomatitis is a common infection of mouth and gums, leading to drooling and swelling. Sometimes lesions in the mouth resembles the canker sores. This infection is common among children. Increasing incidence of gingivostomatitis is expected to boost the market growth. For instance, according to the Journal of Dental Health, Oral Disorders & Therapy, an article - A Case Report on Symptomatic Primary Herpetic Gingivostomatitis, published in December 2017, states that primary herpetic gingivostomatitis (PHG) is a common pediatric infection usually seen before 6 years of age, which is mostly i.e. 90% caused by Herpes Simplex Virus (HSV) type 1.
The global chronic gingivostomatitis treatment market is estimated to be valued at US$ 12,922.5 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).
Figure 1. Global Chronic Gingivostomatitis Treatment Market Share (%), by Region, 2020
Major players offering effective products is expected to propel growth of the global chronic gingivostomatitis treatment market
Major players in the market are focused on offering effective products for chronic gingivostomatitis treatment, which is expected to boost the market growth over the forecast period. For instance, GlaxoSmithKline offers Zovirax, a cream with active ingredient, aciclovir, for antiviral treatment for cold sores.
Moreover, other major players also offers generic drugs from other manufacturers. For instance, HERITAGE PHARMS INC offers ZOVIRAX (acyclovir), a suspension, a generic version of the GlaxoSmithKlines’ Zovirax.
Chronic Gingivostomatitis Treatment Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2019 | Market Size in 2020: | US$ 12,922.5 Mn |
Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: | 6.5% | 2027 Value Projection: | US$ 20,175.2 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Chronic Gingivostomatitis Treatment Market Share (%), by Treatment, 2020
Increasing incidence of chronic gingivostomatitis in North America is expected to boost the market growth
North America is expected to hold dominant position in the global chronic gingivostomatitis treatment market, owing to increasing new cases of chronic gingivostomatitis in the region. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that there were 115,726 number of patient visits with primary diagnosis during 2006-2013 in the U.S.
Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has caused an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global chronic gingivostomatitis treatment market during the forecast period.
Key Players
Major players operating in the global chronic gingivostomatitis treatment market include Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Diagnosis
- Market Snippet, By Treatment
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- New Product Launches
- Collaborations and Agreements
- Market Trends
- Market Dynamics
- Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Market Scenario
- Impact of COVID-19 Market on the Chronic Gingivostomatitis Treatment Products
- Global Chronic Gingivostomatitis Treatment Market, By Diagnosis, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Physical Examination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Microbial Culture
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Gingivostomatitis Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Non-steroidal Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Antiviral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Antibacterial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Gingivostomatitis Treatment Market, By End User, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospitals & Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Academic & Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Gingivostomatitis Treatment Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- S.
- Canada
- Latin America
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Diagnosis, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Taj Pharmaceutical limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ciron pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & CO., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hoffman La Roche AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eli Lily and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca Plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 35 market data tables and 30 figures on "Chronic Gingivostomatitis Treatment Market” - Global forecast to 2027